A review of standard pharmacological therapy for adult asthma - Steps 1 to 5

Chronic Respiratory Disease

Volumn 12, Issue 2, 2015, Pages 165-176

  Patel, Mitesh ^a   Shaw, Dominick ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Asthma; inhaled corticosteroid; pharmacological; step; agonist

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; BAMBUTEROL; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CLARITHROMYCIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; FORMOTEROL; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; MACROLIDE; MEPOLIZUMAB; METHOTREXATE; NEDOCROMIL; OMALIZUMAB; PLACEBO; SALBUTAMOL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT;

ADD ON THERAPY; ADULT ASTHMA; ADULT DISEASE; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRITISH CITIZEN; BRONCHODILATING ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DYSPHONIA; EOSINOPHIL; HUMAN; INHALER; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MONOTHERAPY; NEUROPHILIC ASTHMA; OROPHARYNX CANDIDIASIS; PATIENT COMPLIANCE; PATIENT REFERRAL; PEAK EXPIRATORY FLOW; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; DISEASE COURSE; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84930341725     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972315573529     Document Type: Review

References (110)

1. Martinez FD, Vercelli D. Asthma. Lancet. 2013 ; 382 (9901). 1360-1372
2. Global Initiative for Asthma. Global strategy for asthma management and prevention, www.ginasthma.org(2014, accessed 4 November 2014).
3. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma 2007. National Institutes of Health.
4. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: SIGN 141, https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/(2014, accessed 4 November 2014).
5. Morrow Brown H. Treatment of chronic asthma with prednisolone: significance of eosinophils in the sputum. The Lancet. 1958 ; 272 (7059). 1245-1247
6. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the world health organization consultation on severe asthma. J Allergy Clin Immunol. 2010 ; 126 (5). 926-938
7. Albertson TE, Schivo M, Gidwani N, et al. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clin Rev Allergy Immunol. 2015 ; 48 (1). 7-30
8. Vernon MK, Wiklund I, Bell JA, et al. What do we know about asthma triggers? a review of the literature. J Asthma. 2012 ; 49 (10). 991-998
9. Walters EH, Walters J. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev. 2000 ; (4). CD001285
10. Royal College of Physicians. Why asthma still kills: the national review of asthma deaths (NRAD) confidential enquiry report, https://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf(2014, accessed 4 November 2014).
11. Shaw DE, Green RH, Bradding P. Asthma exacerbations: prevention is better than cure. Ther Clin Risk Manag. 2005 ; 1 (4). 273-277
12. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc. 2013 ; 10: S143 - S149
13. Beasley R, Weatherall M, Shirtcliffe P, et al. Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma?. J Allergy Clin Immunol. 2014 ; 133 (1). 39-41
14. O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet. 2006 ; 368 (9537). 794-803
15. Raissy HH, Kelly HW, Harkins M, et al. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013 ; 187 (8). 798-803
16. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006 ; 130 (5). 1301-1311
17. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003 ; 361 (9363). 1071-1076
18. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the optima randomized trial. Am J Respir Crit Care Med. 2001 ; 164 (8 Pt 1). 1392-1397
19. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000 ; 343 (5). 332-336
20. Masoli M, Holt S, Weatherall M, et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004 ; 23 (4). 552-558
21. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust. 2003 ; 178 (5). 223-225
22. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med. 1997 ; 337 (20). 1405-1411
23. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009 ; (4). CD005307
24. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009 ; 43 (3). 519-527
25. Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. Am J Respir Crit Care Med. 2005 ; 171 (11). 1202-1208
26. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999 ; 340 (3). 197-206
27. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011 ; 364 (18). 1695-1707
28. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012 ; (5). CD002314
29. Engelkes M, Janssens HM, de Jongste JC, et al. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015 ; 45 (2). 396-407
30. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011 ; 128 (6). 1185-1191
31. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005 ; 352 (15). 1519-1528
32. Boushey HA.. Daily inhaled corticosteroid treatment should not be prescribed for mild persistent asthma. Con. Am J Respir Crit Care Med. 2005 ; 172 (4). 412-414
33. O'Byrne PM.. Daily inhaled corticosteroid treatment should be prescribed for mild persistent asthma. Pro. Am J Respir Crit Care Med. 2005 ; 172 (4). 410-412
34. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2012; ; (12). CD009611
35. O'Byrne PM, Boushey HA. Concluding statement. Am J Respir Crit Care Med. 2005 ; 172 (4). 415-416
36. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 ; 356 (20). 2040-2052
37. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the basalt randomized controlled trial. JAMA. 2012 ; 308 (10). 987-997
38. Papi A, Caramori G, Adcock IM, et al. Rescue treatment in asthma. More than as-needed bronchodilation. Chest. 2009 ; 135 (6). 1628-1633
39. Patel M, Pilcher J, Travers J, et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin Immunol Pract. 2013 ; 1 (1). 83-91
40. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med. 2004 ; 170 (8). 836-844
41. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med. 2005 ; 99 (10). 1263-1267
42. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004 ; 113 (2). 245-251
43. Perrin K, Williams M, Wijesinghe M, et al. Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthma. J Allergy Clin Immunol. 2010 ; 126 (3). 505-510
44. Kazani S, Ware JH, Drazen JM, et al. The safety of long-acting beta-agonists: more evidence is needed. Respirology. 2010 ; 15 (6). 881-885
45. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010 ; 362 (13). 1169-1171
46. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005 ; 171 (2). 129-136
47. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 ; 1: 23-31
48. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013 ; 1: 32-42
49. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006 ; 368 (9537). 744-753
50. Patel M, Pilcher J, Beasley R. Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: the future for uncontrolled adult asthma?. Expert Rev Respir Med. 2013 ; 7 (5). 451-454
51. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014 ; 1: CD003137
52. Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy. 2012 ; 67 (7). 835-846
53. Bradding P, Green RH. Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol. 2010 ; 10 (1). 54-59
54. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 ; 18 (5). 716-725
55. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 ; 178 (3). 218-224
56. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009 ; 34 (4). 812-818
57. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 ; 360 (9347). 1715-1721
58. Diamant Z, Tufvesson E, Bjermer L. Which biomarkers are effective for identifying Th2-driven inflammation in asthma?. Curr Allergy Asthma Rep. 2013 ; 13 (5). 477-486
59. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011 ; 127 (2). 355-360
60. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep. 2005 ; 5 (2). 101-108
61. Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev Respir Med. 2012 ; 6 (2). 223-236
62. Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. J Allergy Clin Immunol. 2014 ; 134 (6). 1260-1268
63. Bateman ED. Treatment adherence in asthmatic patients: the last frontier?. J Allergy Clin Immunol. 2014 ; 134 (6). 1269-1270
64. Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med. 2014 ; 371 (13). 1249-1251
65. Bodzenta-Lukaszyk A, Buhl R, Balint B, et al. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012 ; 49 (10). 1060-1070
66. Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 ; 29 (4). 682-689
67. Busse WW, O'Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax. 2013 ; 68 (6). 513-520
68. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of cochrane systematic reviews. Respir Med. 2006 ; 100 (8). 1297-1306
69. National Institute for Health and Care Excellence. Omalizumab for treating severe persistent allergic asthma: NICE technology appraisal TA278, guidance.nice.org.uk/ta278(2013, accessed 4 November 2014).
70. Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient?. Drugs. 2014 ; 74 (5). 521-533
71. Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014 ; 2 (5). 525-536
72. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012 ; 367 (13). 1198-1207
73. Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2014 ;:
74. Wong EH, Porter JD, Edwards MR, et al. The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med. 2014 ; 2 (8). 657-670
75. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013 ; 68 (4). 322-329
76. Slater M, Rivett DW, Williams L, et al. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax. 2014 ; 69 (7). 673-674
77. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011 ; 66 (10). 910-917
78. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006 ; 368 (9537). 780-793
79. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000 ; 2: CD000391
80. Dean T, Dewey A, Bara A, et al. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev. 2004 ; 1: CD003270
81. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001 ; 2: CD002993
82. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001 ; 2: CD002985
83. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 ; 368 (26). 2455-2466
84. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 ; 371 (13). 1189-1197
85. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 ; 371 (13). 1198-1207
86. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 ; 380 (9842). 651-659
87. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 ; 365 (12). 1088-1098
88. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs. 2014 ; 74 (7). 719-728
89. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012 ; 42 (5). 650-658
90. Thomas A, Lemanske RF, Jackson DJ. Approaches to stepping up and stepping down care in asthmatic patients. J Allergy Clin Immunol. 2011 ; 128 (5). 915-924
91. Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ. 2003 ; 326 (7399). 1115
92. Reddel HK, Gibson PG, Peters MJ, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med. 2010 ; 104 (8). 1110-1120
93. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting beta2-agonist step-off in patients with controlled asthma. Arch Intern Med. 2012 ; 172 (18). 1365-1375
94. Patel M, Shirtcliffe P, Beasley R. The beta-2 agonist debate: is there still a problem?. Curr Opin Allergy Clin Immunol. 2013 ; 13 (1). 58-62
95. Rank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013 ; 131 (3). 724-729
96. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ. 2001 ; 323 (7318). 896-900
97. Ram FS, Wright J, Brocklebank D, et al. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2)agonists bronchodilators in asthma. BMJ. 2001 ; 323 (7318). 901-905
98. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001 ; 5 (26). 1-149
99. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000 ; 117 (2). 542-550
100. van der Wiel E, Postma DS, van der Molen T, et al. Effects of small airway dysfunction on the clinical expression of asthma: a focus on asthma symptoms and bronchial hyper-responsiveness. Allergy. 2014 ; 69 (12). 1681-1688
101. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res. 2014 ; 6 (5). 376-388
102. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs. 2008 ; 68 (12). 1741-1770
103. McCormack PL, Plosker GL. Inhaled mometasone furoate: a review of its use in persistent asthma in adults and adolescents. Drugs. 2006 ; 66 (8). 1151-1168
104. McKeever T, Harrison TW, Hubbard R, et al. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest. 2013 ; 144 (6). 1788-1794
105. Busse WW, Lemanske RF, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010 ; 376 (9743). 826-834
106. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations-a GA(2) LEN-DARE systematic review. Allergy. 2011 ; 66 (4). 458-468
107. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013 ; 2: CD000364
108. Public Health England. Influenza: the Green Book Chapter 19, https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19(2014, accessed 4 November 2014).
109. Eisner MD, Iribarren C. The influence of cigarette smoking on adult asthma outcomes. Nicotine Tob Res. 2007 ; 9 (1). 53-56
110. Stapleton M, Howard-Thompson A, George C, et al. Smoking and asthma. J Am Board Fam Med. 2011 ; 24 (3). 313-322